Seattle Genetics Inc. and Astellas Pharma Inc. said FDA has granted Breakthrough Therapy Designation to enfortumab vedotin, an antibody-drug conjugate, for patients with locally advanced or metastatic urothelial cancer who were previously treated with checkpoint inhibitors.
Hologic, Inc. said the Clarity HD high-resolution 3D imaging and Intelligent 2D imaging technology has received PMA approval from FDA and are now available on the 3Dimensions breast tomosynthesis system.
Bristol-Myers Squibb Co. said FDA has accepted its supplemental Biologics License Application for Opdivo (nivolumab) in combination with Yervoy (ipilimumab) for the treatment of adults with microsatellite instability-high or mismatch repair deficient metastatic colorectal cancer that has progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan.
Interim results from a randomized clinical trial for patients with desmoid tumors or aggressive fibromatosis show that the drug sorafenib tosylate (Nexavar) extended progression-free survival compared with a placebo. Based on these interim results, the data and safety monitoring board overseeing the trial recommended that the primary results of the study be released.
TESARO Inc. announced the presentation of maturing data from the TOPACIO trial of Zejula (niraparib) in combination with Keytruda (pembrolizuma) during a plenary session at the 2018 Society for Gynecologic Oncology Annual Meeting on Women's Cancer in New Orleans.
A retrospective analysis of the phase III NOVA trial identified two baseline characteristics, patient body weight less than 170 pounds (77 kilograms) or platelet count of <150,000/µL to be significant factors for grade III or IV thrombocytopenia.
Breast Cancer Research Program: Applications submitted to the FY18 BCRP must address one or more of the following overarching challenges:
The American Association for Cancer Research and AstraZeneca formed a partnership to help foster the next generation of cancer research scientists and stimulate innovative research in the areas of DNA Damage Response in cancer and Immuno-Oncology. This funding opportunity, funded by a grant of $2.9 million from AstraZeneca, will provide support for 12 meritorious postdoctoral... […]
The Society of Surgical Oncology has awarded the Charles Balch Distinguished Service Award to Norman Wolmark and Bernard Fisher for their work with the National Surgical Adjuvant Breast and Bowel Project.
The National Comprehensive Cancer Network announced the recipients of 2018 awards for service to patients and contributions to the alliance, during the NCCN 23rd Annual Conference in Orlando.
